

Rev Esp Cardiol. Influence of neoatherosclerosis on prognosis and treatment response in patients with in-stent restenosis

SUPPLEMENTARY DATA

Tabla 1 of the supplementary data

Baseline clinical, angiographic and procedural characteristics in patients in the RIBS IV and V trials included or not in the OCT substudy

	No OCT n = 434 (87%)	OCT n = 64 (13%)	P
Age, y	66 ± 10	65 ± 12	.56
Female sex	66 (15)	11 (17)	.68
Risk factors			
<i>Diabetes mellitus</i>	168 (39)	22 (34)	.51
Insulin-dependent	64 (15)	6 (9)	.25
<i>Hyperlipidemia</i>	321 (74)	41 (64)	.10
<i>Hypertension</i>	323 (74)	44 (69)	.34
<i>Eversmoker</i>	259 (60)	43 (67)	.25
Clinical features			.95
<i>Unstable angina</i>	213 (49)	26 (41)	.21
<i>Previous myocardial infarction</i>	222 (51)	41 (64)	.05
<i>Previous bypass surgery</i>	41 (9)	3 (5)	.21
<i>Time to restenosis, d</i>	517 [226-1703] 1169 ± 1362	237 [233-2006] 1143 ± 1327	.55 .28
<i>Ejection fraction, %</i>	58 ± 11	62 ± 13	.01
Target artery			.38
<i>Left anterior descending</i>	192 (44)	28 (44)	
<i>Left circumflex</i>	88 (20)	16 (25)	
<i>Right coronary</i>	137 (32)	20 (31)	
<i>Graft</i>	17 (4)	0 (0)	

Previous ST type			.45
<i>BMS</i>	162 (37)	27 (42)	
<i>DES</i>	272 (63)	37 (58)	
<i>Length previous stent, mm</i>	20 ± 7	20 ± 7	.76
Procedural characteristics			
<i>Treatment strategy</i>			.59
PCB	219 (51)	30 (47)	
EES	215 (50)	34 (53)	
<i>Length new EES/PCB, mm</i>	20 ± 8	21 ± 7	.21
<i>Maximal pressure, atm</i>	19 ± 4	20 ± 4	.003
<i>Inflation time, sec (+)</i>	83 ± 51	103 ± 55	.06
	80 [40-105]	100 [60-120]	.02
<i>Maximal balloon</i>	3.13 ± 0.5	2.99 ± 0.4	.01
<i>Balloon-to-artery ratio</i>	1.21 ± 0.2	1.21 ± 0.2	.99
<i>Crossover</i>	14 (3)	0 (0)	.23
<i>Angiographic success</i>	434 (100)	64 (100)	1

BMS, bare metal stent; DES, drug-eluting stent; EES, everolimus eluting stent; OCT, optical coherence tomography; PCB, paclitaxel coated balloon.

The data are expressed as No. (%), mean ± standard deviation, or median [interquartile range].

Table 2 of the supplementary data

Angiographic results in patients in the RIBS IV and V trials included or not in the OCT substudy

	No OCT n = 434 (87%)	OCT n = 64 (13%)	<i>P</i>
<i>Mehran I,II,III-IV</i>	232 (54), 162 (37), 40 (9)	36 (56), 22 (34), 6 (9)	.90
<i>B2-C lesion</i>	203 (47)	34 (53)	.34
<i>Edge-ISR</i>	74 (17)	14 (22)	.35
<i>Quantitative findings</i>	(n = 434)	(n = 64)	
<i>Before the procedure</i>			
Reference vessel diameter, mm	2.65 ± 0.5	2.54 ± 0.5	.11
Minimum lumen diameter, mm	0.86 ± 0.4	0.77 ± 0.3	.05
Stenosis (% of lumen diameter)	67 ± 16	69 ± 13	.31
Lesion length, mm	11.6 ± 6	12.9 ± 7	.14
Diffuse lesions, ≥ 10 mm	209 (49)	37 (60)	.11
<i>After the procedure</i>			
Reference vessel diameter, mm	2.62 ± 0.5	2.51 ± 0.5	.11
Minimum lumen diameter, mm	2.22 ± 0.5	2.06 ± 0.5	.016
Stenosis (% of lumen diameter)	15 ± 11	17 ± 12	.16
Acute gain, mm	1.36 ± 0.5	1.31 ± 0.5	.47
<i>At follow-up</i>	(n = 380)	(n = 62)	
Reference vessel diameter, mm	2.68 ± 0.6	2.57 ± 0.5	.13
Minimal lumen diameter, mm	2.04 ± 0.7	1.89 ± 0.7	.10
Stenosis (% of lumen diameter)	23 ± 21	26 ± 24	.37
Restenosis	43 (11)	11 (18)	.15
Late loss, mm (mean/median)	0.18 ± 0.7 / 0.06 (-0.19 to 0.41)	0.22 ± 0.6 / 0.07(-0.12 to 0.39)	.69 .86
Loss index (mean/median)	0.08 ± 0.6 / 0.04 (-0.15 to 0.29)	0.17 ± 0.5 / 0.07 (-0.12 to 0.39)	.23 .66

Net gain, mm	1.18 ± 0.7	1.09 ± 0.7	.39
--------------	------------	------------	-----

ISR, in stent restenosis; OCT, optical coherence tomography.

The data are expressed as No. (%), mean ± standard deviation or median [interquartile range].